LE WE PMID CA
Diabetes mellitus (t Incretins)11271Diabetes mellitus (t Inkretine)

Alogliptin

Diabetes mellitus (Beta cell decay)

Diabetes mellitus (t Incretins)

Diabetes mellitus T2DM (Type2)

ERS UFR (Pharmacology)

Exenatide

GLP1 Glucagon like peptide1

GLP2 Glucagon like peptide2

Liraglutide

Liver (Steatohepatosis)

Metformin

Saxagliptin

Sitagliptin

Thiazolidinediones

Vildagliptin

2011  
1
The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes.
[21340625] Diabetologia 54(5): 1098-108 (2011)
2010  
2
Liraglutide in the management of type 2 diabetes.
[21116334] Drug Des Devel Ther 4(-): 279-90 (2010)
2010  
3
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
[20859539] Vasc Health Risk Manag 6(-): 671-90 (2010)
2011  
4
Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies.
[21415917] Vasc Health Risk Manag 7(-): 49-57 (2011)
2007  
5
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes.
[17580730] Vasc Health Risk Manag 3(2): 203-10 (2007)
2007  
6
Gliptins: a new class of oral hypoglycaemic agent.
[17881415] QJM 100(11): 671-7 (2007)
2009  
7
Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors.
[19952301] Cleve Clin J Med 76 Suppl 5(-): S28-38 (2009)
2008  
8
What role will 'gliptins' play in glycemic control?
[18491437] Cleve Clin J Med 75(4): 305-10 (2008)
2010  
9
Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.
[21106865] Mayo Clin Proc 85(12 Suppl): S27-37 (2010)
2010  
10
Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus.
[21106866] Mayo Clin Proc 85(12 Suppl): S38-49 (2010)
2010  
11
A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus.
[21106868] Mayo Clin Proc 85(12 Suppl): S5-S14 (2010)
2010  
12
The evolving place of incretin-based therapies in type 2 diabetes.
[20130920] Pediatr Nephrol 25(7): 1207-17 (2010)
2008  
13
Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
[18769687] Medscape J Med 10(7): 171 (2008)
2008  
14
Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.
[18292465] Endocr Rev 29(3): 367-79 (2008)
2007  
15
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
[17622601] JAMA 298(2): 194-206 (2007)
2008  
16
Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.
[19260377] Acta Biomed 79(3): 184-91 (2008)
2009  
17
Liraglutide in type 2 diabetes: from pharmacological development to clinical practice.
[19848045] Acta Biomed 80(2): 93-101 (2009)
2010  
18
The incretin system and cardiometabolic disease.
[20151054] Can J Cardiol 26(2): 87-95 (2010)
2009  
19
Incretin-based therapies: viewpoints on the way to consensus.
[19875556] Diabetes Care 32 Suppl 2(-): S223-31 (2009)
2008  
20
The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions.
[19036624] Diabetes Metab 34(6 Pt 1): 550-9 (2008)
2008  
21
The role of incretins in glucose homeostasis and diabetes treatment.
[19074620] Pharmacol Rev 60(4): 470-512 (2008)
2006  
22
What are incretins, and how will they influence the management of type 2 diabetes?
[16981805] J Manag Care Pharm 12(7 Suppl A): S2-12; quiz S14-6 (2006)
2004  
23
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.
[15271645] Am J Physiol Endocrinol Metab 287(2): E199-206 (2004)
2004  
24
Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells.
[15140754] Am J Physiol Endocrinol Metab 286(6): E875-81 (2004)
2004  
25
Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
[15140755] Am J Physiol Endocrinol Metab 286(6): E882-90 (2004)
2008  
26
New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.
[18227398] Circulation 117(4): 574-84 (2008)
2004  
27
The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism.
[15561911] Diabetes 53 Suppl 3(-): S197-204 (2004)
2004  
28
Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.
[15561910] Diabetes 53 Suppl 3(-): S190-6 (2004)
2004  
29
Therapeutic strategies based on glucagon-like peptide 1.
[15331525] Diabetes 53(9): 2181-9 (2004)
2002  
30
The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion.
[12475787] Diabetes 51 Suppl 3(-): S434-42 (2002)
2007  
31
Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action.
[17337495] Diabetes Care 30(6): 1335-43 (2007)
2007  
32
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
[17337494] Diabetes Care 30(6): 1344-50 (2007)
2006  
33
Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1.
[16443905] Diabetes Care 29(2): 435-49 (2006)
2008  
34
DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
[18640591] Diabetes Metab 34 Suppl 2(-): S91-5 (2008)
2008  
35
Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
[18640590] Diabetes Metab 34 Suppl 2(-): S78-90 (2008)
2008  
36
GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival.
[18640589] Diabetes Metab 34 Suppl 2(-): S73-7 (2008)
2008  
37
Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes.
[18640588] Diabetes Metab 34 Suppl 2(-): S65-72 (2008)
2005  
38
Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.
[16142014] Diabetes Metab 31(3 Pt 1): 233-42 (2005)
2003  
39
Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis.
[14645210] Endocrinology 144(12): 5145-8 (2003)
2008  
40
Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
[18322302] Eur J Endocrinol 158(6): 773-84 (2008)
2000  
41
Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function.
[11124853] Eur J Endocrinol 143(6): 717-25 (2000)
2008  
42
Incretin-based therapies in type 2 diabetes mellitus.
[18628530] J Clin Endocrinol Metab 93(10): 3703-16 (2008)
2008  
43
The GLP-1 concept in the treatment of type 2 diabetes--still standing at the gate of dawn?
[18258781] J Clin Endocrinol Metab 93(2): 375-7 (2008)
2011  
44
The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.
[21765869] Therap Adv Gastroenterol 4(4): 249-63 (2011)
2007  
45
The pathophysiologic role of incretins.
[17724014] J Am Osteopath Assoc 107 Suppl(-): S6-9 (2007)
2007  
46
Application of incretin mimetics and dipeptidyl peptidase IV inhibitors in managing type 2 diabetes mellitus.
[17724013] J Am Osteopath Assoc 107 Suppl(-): S10-6 (2007)
2003  
47
Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.
[14529486] Curr Med Chem 10(22): 2471-83 (2003)
2010  
48
2010  
49
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin.
[21437074] Diabetes Metab Syndr Obes 3(-): 31-41 (2010)
2010  
50
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review.
[21437085] Diabetes Metab Syndr Obes 3(-): 155-63 (2010)
2009  
51
Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus.
[21437116] Diabetes Metab Syndr Obes 2(-): 23-30 (2009)
2009  
52
Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes.
[21437121] Diabetes Metab Syndr Obes 2(-): 83-90 (2009)
2009  
53
Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes.
[21437127] Diabetes Metab Syndr Obes 2(-): 135-44 (2009)
2009  
54
Alogliptin: a new addition to the class of DPP-4 inhibitors.
[21437125] Diabetes Metab Syndr Obes 2(-): 117-26 (2009)
2011  
55
Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials.
[21584276] Exp Diabetes Res 2011(-): 215764 (2011)
2011  
56
Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass.
[21716694] Exp Diabetes Res 2011(-): 376509 (2011)
2011  
57
From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.
[21747834] Exp Diabetes Res 2011(-): 898913 (2011)
2010  
58
Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.
[21701614] Drug Healthc Patient Saf 2(-): 7-19 (2010)
2011  
59
Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
[21966329] Open Med Chem J 5(Suppl 2): 82-92 (2011)
2011  
60
2009  
61
Gliptins: a new class of oral antidiabetic agents.
[20376212] Indian J Pharm Sci 71(6): 608-14 (2009)
2009  
62
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
[19801361] J Am Pharm Assoc (2003) 49 Suppl 1(-): S16-29 (2009)
2008  
63
The entero-insular axis: implications for human metabolism.
[18020966] Clin Chem Lab Med 46(1): 43-56 (2008)
2003  
64
Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.
[12554744] Mol Endocrinol 17(2): 161-71 (2003)
2010  
65
Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.
[21143938] BMC Endocr Disord 10(): 20 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



  • Diabetes mellitus (t Inkretine)

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia